Total Revenue

Down 18% (from $225,131 to $184,473)

Revenue decreased by $40,658, largely due to intensified competition in the cannabis telemedicine industry that has been negatively impacting demand, a trend observed in previous periods as well. " "

Net Loss

Improved by nearly 52% (from $222,568 to $107,364)

Net loss narrowed significantly, reflecting successful cost control measures that helped reduce operating and non-operating expenses compared to the previous period, contributing to overall improved profitability performance despite a lower revenue base. " "

Operating Expenses

Down 27% (from $300,904 to $218,581)

Operating expenses were trimmed by $82,323, building on earlier cost-cutting initiatives; reductions in wages, salaries, and other overheads have helped lower overall expenses in Q1 2025 relative to Q1 2024. " "

Wages & Salaries

Down from $114,071 to $73,390

Employee costs decreased by approximately $40,681, demonstrating continued aggressive cost management in personnel expenses, a measure already emphasized in earlier periods. " "

Cash Flow

Turned from –$24,744 to +$4,129

A positive shift in operating cash flow by nearly $28,873 was achieved due to tighter cash management and improved efficiency in operations, marking a reversal of the negative trend observed in Q1 2024. " "

Gross Margin

Improved from 56% to 63%

Gross margin increased despite a drop in absolute gross profit (from $126,113 to $116,967) because cost of sales declined more than revenue, reflecting enhanced cost leverage and pricing strategies implemented over prior periods. " "